In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months. Despite hospital launches taking time, we expect the uptake of Dsuvia to drive revenue upside beyond the Street's current estimates, which, in turn, could drive the stock higher from current levels,” Follked opined. We believe that Dsuvia offers an advancement in delivery of adequate pain treatment by eliminating the need for an invasive and time-consuming IV set-up in the emergency room, as well as an outpatient, or post-surgery, setting. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. “With the launch of Dsuvia, we believe investor focus can now shift to launch metrics and peak sales potential for the product. ![]() The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year.Īgainst this backdrop, several members of the Street believe ACRX’s $1.40 share price looks like a steal.Ĭantor analyst Brandon Folkes is upbeat on Dsuvia’s prospects as an alternative to current opioid treatments, and he believes that potential will boost the company’s stock. In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. We are talking returns of at least 300% over the next 12 months, according to the analysts. Not to mention substantial upside potential is on the table. The platform steered us towards two tickers sporting “Strong Buy” consensus ratings from the analyst community. Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. It is for this reason that we would encourage investors to build their portfolios now and see things through in the event of any consolidation phase that may come in Q1,” Lecubarri wrote. Such a positive backdrop is likely to keep investors chasing those few stocks that still offer big recovery upside, as they seem to have started to do YTD. However, the year long outlook is encouraging due to far more powerful fundamental tailwinds. “1Q may be rocky following the strong gains since Nov and the fact that valuations are sitting on all-time highs. JPMorgan's Head of Small and Midcap Equity Strategy, Eduardo Lecubarri, sees both the opportunities and dangers in the current market environment – and the great potential of small-cap stocks that have room to run. ![]() With that low price comes the potential for extreme gains, as even an incrementally small price increase will translate to a high percentage gain. Among the best exemplars of this axiom are the penny stocks, those equities priced at $5 or less. Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |